<DOC>
	<DOCNO>NCT01194427</DOCNO>
	<brief_summary>This research study design look effect combination vorinostat ( Suberoylanilide Hydroxamic Acid Zolinza ) tamoxifen breast cancer tissue . The investigator compare tissue original breast biopsy tissue obtain take vorinostat tamoxifen 2 week .</brief_summary>
	<brief_title>A Study Vorinostat Tamoxifen Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description>Key eligibility criterion include : - Newly diagnose invasive breast cancer await surgery neoadjuvant ( preoperative ) treatment - No use hormone contraceptive replacement therapy within 30 day prior diagnostic breast cancer biopsy ( unless willing additional biopsy prior start study ) - No prior current use therapy treat current breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Stage IIII invasive breast cancer Awaiting surgery neoadjuvant treatment ECOG performance status 0 , 1 2 Adequate organ function Prior use hormone contraception replacement therapy must discontinue least 30 day prior diagnostic biopsy ( unless participant willing undergo additional biopsy study ) Prior current treatment kind current breast cancer Current use investigational drug Uncontrolled active infection , congestive heart failure , cardiac arrythmia , psychiatric illness</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Preoperative</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>